Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Top Cited Papers
- 8 December 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 59 (5), 561-574
- https://doi.org/10.1007/s00280-006-0393-4
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- BAY 43-9006 Inhibition of Oncogenic RET MutantsJNCI Journal of the National Cancer Institute, 2006
- Angiogenesis as a therapeutic targetNature, 2005
- Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid TumorsClinical Cancer Research, 2005
- Renal cell carcinoma: review of novel single-agent therapeutics and combination regimensAnnals of Oncology, 2005
- VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-κB-dependent mechanismOncogene, 2004
- Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesisHematology/Oncology Clinics of North America, 2004
- Role of Raf in Vascular Protection from Distinct Apoptotic StimuliScience, 2003
- Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsJCI Insight, 2003
- Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawalJCI Insight, 1999
- A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGFDevelopment, 1998